Guiding Immunotherapy in Limited-Stage Small Cell Lung Cancer with ctDNA
In this article
ctDNA to Guide Immunotherapy in Limited-Stage SCLC
After CRT, consolidation IO benefit clusters in ctDNA-positive patients; minimal added benefit in ctDNA-negative.
Why it matters
Following ADRIATIC, CRT→durvalumab is standard. Yet not all benefit equally. Early ctDNA status may triage who truly needs consolidation IO.
What is ctDNA?
Tumor-derived DNA fragments in blood (“liquid biopsy”). This study used a fixed 139-gene lung panel and ~30,000× ultra-deep NGS.
Key numbers
PFS by early ctDNA
11.4 vs 49.4 mo
ctDNA+ vs ctDNA− post-induction
(HR 2.46; P<.001)
IO benefit (ctDNA+)
HR 0.29 / 0.05
PFS / OS improvement (P=.013 / P<.001)
IO benefit (ctDNA−)
NS
PFS HR 1.30; OS HR 1.14 (no added benefit)
PFS (months) — ctDNA+ vs ctDNA−
● ctDNA(+) ● ctDNA(−)
IO effect by ctDNA status
PFS HR & OS HR
P=.013 / P<.001
Not statistically significant
Who benefits from IO?
- ctDNA(+): clear PFS/OS gain with consolidation IO.
- ctDNA(−): little/no benefit; consider de-escalation.
ctDNA + Radiologic Response
Low risk ctDNA− & ≥60% shrink → excellent prognosis.
Mid risk Mixed features → IO benefit uncertain.
High risk ctDNA+ & <60% shrink → largest IO benefit (PFS HR 0.24; OS HR 0.06).
Assay: Tumor-agnostic fixed panel (not tumor-informed MRD). Mutations are predefined by the panel; blood is queried directly.
Data: WCLC 2025 (Bi N, et al.); ADRIATIC NEJM 2023 • 144 LS-SCLC pts; CRT±IO (serplulimab)
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.